Additional Information

Description

Benlysta (Belimumab 120 mg/5 mL) is a monoclonal antibody that functions as a B-lymphocyte stimulator (BLyS)-specific inhibitor. It is indicated for the treatment of active, autoantibody-positive systemic lupus erythematosus (SLE) in patients aged 5 years and older who are receiving standard therapy. By inhibiting BLyS, belimumab reduces the survival of autoreactive B cells, thereby lowering disease activity and preventing disease flares.

Benlysta is supplied as a sterile, preservative-free, lyophilized powder for intravenous infusion. Each single-dose vial contains 120 mg of belimumab in a 5-mL volume. The formulation requires reconstitution and dilution prior to administration. The product is provided in a glass vial with a rubber stopper (not made with natural rubber latex) and a flip-off seal.

The medication is administered via intravenous infusion over one hour at intervals specified by the treatment regimen. Premedication with antihistamines and antipyretics may be required to reduce the risk of infusion-related reactions. Common adverse effects include nausea, diarrhea, infusion reactions, headache, and increased infection risk.